Perrigo Claims Reckitt's Bid To Block Generic Mucinex Is "Baseless"
This article was originally published in The Tan Sheet
Reckitt Benckiser's petition seeking to define specific bioequivalence standards for private-label versions of Mucinex OTC cough products, if followed, would push FDA to violate generic drug law, Perrigo argues
You may also be interested in...
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
In an attempt to delay private-label competition for Mucinex OTC cough products, Reckitt Benckiser asks FDA to ensure potential generics meet the same bioequivalence across the 12-hour dosing interval as the branded product
Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM